Institutional & Family Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Institutional & Family Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$329	Hold	13	–	–	﹤0.01%	718
2024 Q1	$402	Hold	13	–	–	﹤0.01%	702
2023 Q4	$525	Buy	+13	New	+$390	﹤0.01%	666
2022 Q1	–	Sell	-6	Closed	–	–	775
2021 Q4	$0	Sell	6 -7	-54%	-$296	﹤0.01%	801
2021 Q3	$1K	Sell	13 -8	-38%	-$429	﹤0.01%	815
2021 Q2	$1K	Hold	21	–	–	﹤0.01%	870
2021 Q1	$1K	Sell	21 -12	-36%	-$785	﹤0.01%	841
2020 Q4	$2K	Buy	+33	New	+$1.59K	﹤0.01%	747

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Institutional & Family Asset Management's BBIO Position: Q2 2024 in Review

Institutional & Family Asset Management held its BridgeBio Pharma (BBIO) position steady in Q2 2024 at 13 shares worth $329. The position accounts for ﹤0.01% of the portfolio, ranked #718.

Institutional & Family Asset Management first reported a position in BBIO in Q4 2020 and has held it in 8 quarters since. The position peaked at $2K in Q4 2020. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

Institutional & Family Asset Management held 13 shares of BridgeBio Pharma worth $329 as of Q2 2024.
Institutional & Family Asset Management left its BridgeBio Pharma share count unchanged in Q2 2024.
BridgeBio Pharma made up ﹤0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #718 holding.
Institutional & Family Asset Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 8 quarters since.
Institutional & Family Asset Management's BridgeBio Pharma position peaked at $2K in Q4 2020.
251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.